Search

Mirati Therapeutics Inc

Lezárt

SzektorEgészségügy

0

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

Maximum

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

-0.05% downside

Hangulat hírek alapján

By Acuity

50%

50%

113 / 339 Rangsor szerint Healthcare

Mirati Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 25. 23:51 UTC

News

CDW Corp completed its acquisition of Lovelytics, enhancing its Services and Solutions portfolio, as shares advanced in after-market trading.

2026. szept. 25. 23:51 UTC

News

AbbVie Inc received FDA approval for Juvmo (Tavapadon), a Parkinson's treatment, contributing to a modest rise in shares during after-market trading.

2026. szept. 25. 23:35 UTC

News

DICK'S Sporting Goods faces two class action lawsuits alleging misleading financial statements, contributing to a modest decline in after-market trading.

2026. szept. 25. 23:15 UTC

News

Skyworks Solutions Inc. has extended the expiration date for Qorvo's senior notes exchange offers to October 2, 2026, with shares modestly higher in after-market trading.

2026. szept. 25. 23:05 UTC

News

PepsiCo plans to raise prices on select chips and sodas by late 2026 or early 2027 due to inflation and rising commodity costs, with stock roughly flat in after-market trading.

2026. szept. 25. 23:05 UTC

News

Vicor Corp raised its third-quarter revenue growth outlook to over 20%, doubling its previous forecast, following a new OEM licensing agreement. Shares advanced in after-market trading.

2026. szept. 25. 23:05 UTC

News

Moody's affirmed BJ's Wholesale Club's Ba1 rating and revised its outlook to positive, contributing to the asset's modest rise in after-market hours.

2026. szept. 25. 23:05 UTC

News

Coca-Cola Consolidated Inc appointed Rob Gehring to lead North American operations, effective December 1, as the stock trades lower in after-market hours.

2026. szept. 25. 23:05 UTC

News

Synopsys Inc is higher in after-market trading following HSBC's new price target of $700, citing AI's potential to enhance revenue capabilities.

2026. szept. 25. 23:05 UTC

Event
News

Merck & Co. has withdrawn its Biologics License Application for ifinatamab deruxtecan after the FDA indicated insufficient trial data, with shares trading lower in after-market hours.

2026. szept. 25. 23:05 UTC

News

Monster Beverage shares are modestly lower in after-market trading following CEO Rob Gehring's resignation announcement effective November 30, 2026.

2026. szept. 25. 23:05 UTC

News

McDonald's Corp plans an $8.5 billion menu overhaul to introduce healthier options, with shares edging higher in after-market trading.

2026. szept. 25. 23:01 UTC

News

Kodiak Sciences Inc. shares rose in after-market trading as the company announced topline results from its DAYBREAK Phase 3 study will be released on September 28, 2026.

2026. szept. 25. 23:01 UTC

News

Chevron Corp's shares rose in after-market trading as the company accelerates plans to export gas from Cyprus's Aphrodite field through Egypt's LNG facilities.

2026. szept. 25. 23:01 UTC

News

Marathon Petroleum's stock is higher in after-market hours as the White House reviews a potential diesel export ban that could impact earnings.

2026. szept. 25. 23:01 UTC

News

PayPal shares rose in after-market hours amid speculation of a potential all-stock takeover and Deutsche Bank's price target increase to $55 from $50.

2026. szept. 25. 22:50 UTC

News

S&P Global Ratings downgraded Cable One's credit rating to 'B+' amid increased competition, but the stock has advanced in after-market trading following five consecutive lower sessions.

2026. szept. 25. 22:45 UTC

News

Viatris Inc is seeing a modest increase in after-market trading after filing a lawsuit against Novo Nordisk over its planned generic Wegovy.

2026. szept. 25. 22:15 UTC

News

Fox Factory Holding Corp. completed the $225 million sale of Marucci Sports, reducing leverage and interest expenses, leading to higher shares in after-market hours.

2026. szept. 25. 22:01 UTC

News

S&P Global Ratings upgraded Rithm Capital Corp's credit rating to 'B+' as the firm diversifies revenue, with assets under management rising to $61 billion.

2026. szept. 25. 21:02 UTC

News

The New York Times Company declared a quarterly dividend of $0.23 per share, while the stock traded modestly lower in after-market hours.

2026. szept. 25. 21:01 UTC

News

Best Buy Co., Inc. plans to sell debt securities, contributing to a modest decline in after-market trading, with shares lower since Friday's close.

2026. szept. 25. 20:08 UTC

Social Media
News

Moderna Inc's stock advanced following CEO Stéphane Bancel's comments on focusing on cancer vaccines and recent positive trial results for its melanoma vaccine.

2026. szept. 25. 20:08 UTC

Social Media
News

Apple shares are advancing as Bernstein maintains a Buy rating with a $370 price target, despite lowering EPS estimates for Q1 to $2.87.

2026. szept. 25. 20:08 UTC

News

ON Semiconductor Corp shares are sharply higher, driven by the launch of its Embedded Power Platform and strengthened partnerships in automotive and AI sectors.

2026. szept. 25. 20:08 UTC

News

C3.ai Inc shares declined modestly as options sentiment remained mixed, with a put/call ratio of 0.33 and implied volatility in the lowest 10% of observations.

2026. szept. 25. 20:08 UTC

News

Snowflake Inc. shares are advancing as the company partners with CrowdStrike to integrate its AI-native Falcon platform into the Snowflake Marketplace.

2026. szept. 25. 20:08 UTC

Correlated Moves
News

Box Inc shares fell as the resignation of Chief Accounting Officer Eli Berkovitch may have contributed to the stock's ongoing decline, marking six consecutive days lower.

2026. szept. 25. 20:08 UTC

Social Media
News

Amazon.com Inc. saw moderately bullish options activity, with calls outpacing puts and a put/call ratio of 0.43, amid rising sentiment for October call options.

2026. szept. 25. 20:08 UTC

News

Aflac shares fell today as Japan Post Holdings sold 12.2k shares, contributing to a price move slightly below Thursday's close.

Társak összehasonlítása

Árváltozás

Mirati Therapeutics Inc Előrejelzés

Célár

By TipRanks

-0.05% elmozdulás lefelé

12 hónapos előrejelzés

Átlag 58.67 USD  -0.05%

Magas 59 USD

Alacsony 58 USD

5 Wall Street elemző 12 hónapos célárain alapulva a(z)Mirati Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

5 ratings

0

Vétel

5

Tartás

0

Eladás

Hangulat

By Acuity

113 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

EBITDA

Üzemi nyereség

$

Rólunk Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.